Dxcover is a clinical-stage liquid biopsy company based in Glasgow, founded in 2016 by David S Palmer, Holly Butler, and Matthew Baker. The firm focuses on developing innovative diagnostics for the early detection of various cancers, which is crucial for improving treatment outcomes. Dxcover has pioneered the use of infrared spectroscopy combined with artificial intelligence to analyze circulating pan-omic indicators, allowing for the identification of cancer from a simple blood sample. This approach enables same-day diagnosis and patient stratification, facilitating timely interventions. The company has demonstrated strong clinical data supporting the accurate diagnosis of Stage I and Stage II cancers, underscoring its commitment to enhancing survival rates and quality of life for patients.
OxCan is a startup that uses machine learning and liquid biopsy for early lung cancer detection.
52 North Health aims to improve healthcare with a medical device that uses artificial intelligence (AI) to determine the risk of neutropenic sepsis for patients undergoing chemotherapy.
Leo Cancer Care is focused on revolutionizing cancer radiation therapy by offering a treatment system designed to enhance patient experience and outcomes. Founded in Australia, the company leverages global research that highlights the benefits of upright patient positioning during treatment. This innovative approach shifts the traditional paradigm of machine rotation to patient rotation, allowing for a more controlled and efficient therapy process. The system integrates advanced 3D imaging and precise radiation beam management, ensuring that the appropriate amount of energy is delivered to targeted tissues. By streamlining cancer treatment and connecting patients to centralized care centers, Leo Cancer Care aims to reduce both the physical discomfort and costs typically associated with chemotherapy and radiation therapy, ultimately putting patients in control of their treatment journey.
52 North Health aims to improve healthcare with a medical device that uses artificial intelligence (AI) to determine the risk of neutropenic sepsis for patients undergoing chemotherapy.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at
support@teaserclub.com. Your feedback is most welcome.